Allan Goldstein - RegeneRx Biopharmaceutica Insider

RGRX -- USA Stock  

USD 0.20  0.01  4.76%

  Chairman
Dr. Allan L. Goldstein Ph.D. is Chairman of the Board, Chief Scientific Advisor of the Company. He is Emeritus Professor former Chairman of the Department of Biochemistry and Molecular Medicine at the George Washington University School of Medicine and Health Sciences. Dr. Goldstein is a recognized expert in the field of immunology and protein chemistry, having authored over 435 scientific articles in professional journals. He is also the inventor on over 25 issued andor pending patents in biochemistry, immunology, cardiology, cancer and wound healing. Dr. Goldstein discovered several important compounds, including Ta1, which is marketed worldwide, and Tb4, which is the basis for RegeneRxs clinical program. Dr. Goldstein served on the Board of Trustees of the Sabin Vaccine Institute from 2000 to 2012 and on the Board of Directors of the Richard B. and Lynne V. Cheney Cardiovascular Institute from 2006 to 2012
Age: 77  Chairman Since 1982      
301-208-9191  http://www.regenerx.com
Goldstein has also done pioneering work in the area of medical education, developing distance learning programs for the internet entitled ?Frontiers in Medicine, ? a medical education series that Dr. Goldstein developed. The Board believes that Dr. Goldstein?s scientific expertise, industry background and prior experience as our founder all position him to make an effective contribution to the medical and scientific understanding of the Board, which the committee believes to be particularly important as we continue our Tb4 development efforts.

Management Efficiency

The company has return on total asset (ROA) of (118.7) % which means that it has lost $118.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.5) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 439.35 K in liabilities. RegeneRx Biopharmaceuticals has Current Ratio of 1.2 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Entity Summary

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 , for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceutica operates under Biotechnology classification in USA and traded on OTC Market. It employs 3 people.RegeneRx Biopharmaceuticals (RGRX) is traded on OTC Market in USA. It is located in 15245 Shady Grove Road and employs 3 people.

RegeneRx Biopharmaceutica Leadership Team

J Finkelstein, CEO and President and Director
Don Elsey, Independent Director
Allan Goldstein, Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board
Joseph McNay, Independent Director
Raymond Elsey, Independent Director
Mauro Bove, Independent Director

Stock Performance Indicators

Current Sentiment - RGRX

RegeneRx Biopharmaceutica Investor Sentiment
Macroaxis portfolio users are evenly split in their perspective on investing in RegeneRx Biopharmaceuticals. What is your perspective on investing in RegeneRx Biopharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
S   
Purchased over 500 shares of
few days ago
Traded for 6.08
S   
Purchased over 500 shares of
few days ago
Traded for 6.08
MRN   
Purchased over 100 shares of
few days ago
Traded for 2.17
C   
Purchased over 40 shares of
few days ago
Traded for 71.99
F   
Purchased over 300 shares of
few days ago
Traded for 9.91
Additionally take a look at Your Equity Center. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.